| 词条 | Ublituximab |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 470619391 | type = mab | image = | alt = | mab_type = mab | source = xi/o | target = CD20 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 1174014-05-1 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | KEGG = D11243 | chemical_formula = | molecular_weight = }}Ublituximab is an immunomodulator. It binds to CD20.[1] It is currently in Phase 3 clinical trials for multiple sclerosis.[2] It is also in Phase 2 clinical trials for chronic lymphocytic leukemia. See also
References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}} {{monoclonals for tumors}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^https://clinicaltrials.gov/ct2/show/NCT03277261 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。